348 related articles for article (PubMed ID: 32316926)
1. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.
Lyu C; Zhang Y; Liu X; Wu J; Zhang J
BMC Infect Dis; 2020 Apr; 20(1):296. PubMed ID: 32316926
[TBL] [Abstract][Full Text] [Related]
2. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.
Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH
Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis.
Liu Q; Li W; Feng Y; Tao C
PLoS One; 2014; 9(6):e98091. PubMed ID: 24911658
[TBL] [Abstract][Full Text] [Related]
4. The use of polymyxins to treat carbapenem resistant infections in neonates and children.
Thomas R; Velaphi S; Ellis S; Walker AS; Standing JF; Heath P; Sharland M; Dona' D
Expert Opin Pharmacother; 2019 Mar; 20(4):415-422. PubMed ID: 30576264
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
6. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis.
Lima WG; Brito JCM; Cardoso BG; Cardoso VN; de Paiva MC; de Lima ME; Fernandes SOA
Eur J Clin Microbiol Infect Dis; 2020 Aug; 39(8):1427-1438. PubMed ID: 32533271
[TBL] [Abstract][Full Text] [Related]
7. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.
Du X; Xu X; Yao J; Deng K; Chen S; Shen Z; Yang L; Feng G
Am J Infect Control; 2019 Sep; 47(9):1140-1145. PubMed ID: 31003750
[TBL] [Abstract][Full Text] [Related]
8. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
9. An update on polymyxin susceptibility testing methods for
Dafopoulou K; Vourli S; Tsakris A; Pournaras S
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):699-713. PubMed ID: 31509713
[No Abstract] [Full Text] [Related]
10. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
[TBL] [Abstract][Full Text] [Related]
11. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
Mohd Sazlly Lim S; Naicker S; Ayfan AK; Zowawi H; Roberts JA; Sime FB
Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.
Lemos EV; de la Hoz FP; Einarson TR; McGhan WF; Quevedo E; Castañeda C; Kawai K
Clin Microbiol Infect; 2014 May; 20(5):416-23. PubMed ID: 24131374
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
14. Status of carbapenem-resistant Acinetobacter baumannii harboring carbapenemase: First systematic review and meta-analysis from Iran.
Beigverdi R; Sattari-Maraji A; Emaneini M; Jabalameli F
Infect Genet Evol; 2019 Sep; 73():433-443. PubMed ID: 31176030
[TBL] [Abstract][Full Text] [Related]
15. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation.
Freire MP; Van Der Heijden IM; do Prado GV; Cavalcante LS; Boszczowski I; Bonazzi PR; Rossi F; Guimarães T; D'Albuquerque LA; Costa SF; Abdala E
Transpl Infect Dis; 2014 Jun; 16(3):369-78. PubMed ID: 24725123
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.
Ni W; Cai X; Wei C; Di X; Cui J; Wang R; Liu Y
Braz J Infect Dis; 2015; 19(2):170-80. PubMed ID: 25636193
[TBL] [Abstract][Full Text] [Related]
18. The incidence and prevalence of hospital-acquired (carbapenem-resistant)
Ayobami O; Willrich N; Harder T; Okeke IN; Eckmanns T; Markwart R
Emerg Microbes Infect; 2019; 8(1):1747-1759. PubMed ID: 31805829
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.
Ni W; Han Y; Zhao J; Wei C; Cui J; Wang R; Liu Y
Int J Antimicrob Agents; 2016 Feb; 47(2):107-16. PubMed ID: 26742726
[TBL] [Abstract][Full Text] [Related]
20.
Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
